PROTAGONIST THERAPEUTICS, INC. (PTGX) Free cash flow 2016–2025
PROTAGONIST THERAPEUTICS, INC. (PTGX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$56.1MFY2025 · since FY2016: -$30.3M → $56.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $56.1M | -69.3% |
| FY2024 | $182.8M | +358.0% |
| FY2023 | -$70.8M | +35.0% |
| FY2022 | -$108.9M | +0.0% |
| FY2021 | -$109.0M | -49.4% |
| FY2020 | -$73.0M | -71.7% |
| FY2019 | -$42.5M | +15.7% |
| FY2018 | -$50.4M | -1673.1% |
| FY2017 | $3.2M | +110.6% |
| FY2016 | -$30.3M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice